Presentations Include Data from More than Thirty NanoString-Related Abstracts Including Five Using the GeoMx Digital Spatial Profiler
SEATTLE–(BUSINESS WIRE)–#SITC–NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous abstracts demonstrating advances in understanding of immune response and cancer immunotherapy using the nCounter® and GeoMx™ Digital Spatial Profiler (DSP) platforms that will be presented at the 34th Annual Meeting of the Society of Immunotherapy for Cancer (SITC).
“Immunotherapy represents one of the most exciting fields for developing breakthrough treatments for cancer,” said Brad Gray, president and CEO of NanoString. “We are honored to see the continuing contribution that our nCounter and GeoMx DSP technologies are making toward understanding the mechanism of cancers and the critical role that the immune system plays in predicting patient response.”
More than 30 abstracts using NanoString’s nCounter and GeoMx DSP platforms will be presented at the SITC Annual Meeting, being held Nov. 7–10, 2019, at the Gaylord National Hotel & Convention Center in National Harbor, Md. The research being presented spans a wide breadth of applications, including biomarker development, the study of immune responsiveness and resistance, and digital pathology.
Five studies include the use of NanoString’s GeoMx DSP platform in immuno-oncology research. These abstracts include numbers P3, P24, P30, P126 and P305 that are described below. GeoMx DSP allows for digital quantification of protein and gene expression from discrete regions of FFPE tissue in an automated and multiplex format.
NanoString is currently accepting applications for its Technology Access Program (TAP). To inquire, please e-mail TAP@nanostring.com.
nCounter-based Abstracts
Poster #: P361
Title: Molecular and Immunologic Profiling of CD8+ T Cell Responses in Patients Receiving a Multiple Antigen-Engineered Dendritic Cell Vaccine
Authors: Juraj Adamik, PhD; Patricia M. Santos, PhD; Samuel Du, BS; Lazar Vujanovic, PhD; Timothy Howes; Sarah Warren, PhD; Andrea Gambotto, MD; John M. Kirkwood, MD; Lisa H. Butterfield, PhD
Summary: This study utilized the new CAR-T panel and the PanCancer Immune Profiling panel to understand T cell biology in patients receiving a dendritic cell vaccine
Poster #: P123
Title: Identification of mRNA signatures that predict response to immunotherapy in melanoma patients
Authors: Ioannis A. Vathiotis, MD; Amy Sullivan; Sarah Warren, PhD; Nicole Gianino; Sandra Martinez-Morilla, PhD; Pok Fai Wong, MD, MPhil; Harriet Kluger, MD; Konstantinos N. Syrigos; David L. Rimm, MD, PhD
Summary: This study highlights the utility of the nCounter IO360 Gene Expression Panel and Data Analysis Service for biomarker discovery.
Poster #: P125
Title: Adenosine and AMP gene expression profiles predict response to adenosine pathway therapies and indicate a need for dual blockade of CD73 and A2AR with CD73 inhibitors
Authors: Stephen Willingham, PhD; Drew Hotson, PhD; Jessica Hsieh; Brian Munneke; Long Kwei, PhD; Joseph J. Buggy; Richard A. Miller, MD
Summary: This study investigates potential biomarkers of response for novel IO agents.
GeoMx DSP Abstracts
Poster #: P03
Title: Immune infiltration correlates with TP53 mutational status in a multi-cohort acute myeloid leukemia study
Authors: Sergio Rutella, MD, PhD, FRCPath, Nottingham Trent University, John van Geest Cancer Research Centre and Centre for Health, Ageing and Understanding Disease (CHAUD), Sergio Rutella, MD, PhD, FRCPath, Jayakumar Vadakekolathu, PhD, Stephen Reeder, BS, Jenny Ashforth, Melissa Courtney, Amanda Coutts, PhD, Tressa Hood, MS, Sarah E. Church, PhD, Clare Coveney, PhD, Jan Davidson-Moncada, MD, PhD, Jorn Meinel, MD, Marc Schmitz, MD, Francesco M. Marincola, MD, Martin Bornhauser, MD, Sergio Rutella, MD, PhD, FRCPath
Summary: This study found that P53 mutational status was associated with increase inflammatory gene expression in AML. Additionally, immune infiltrate was evaluated spatially in a subset of samples using GeoMx.
Poster #: P24
Title: Molecularly guided digital spatial profiling for highly multiplexed analysis of gene expression with spatial and single cell resolution
Authors: Anushka Dikshit, PhD; Chris Merritt, PhD; Jamie Rose Kuhar, PhD; Karen Nguyen; Kristina Sorg; Bingqing Zhang; Courtney M. Anderson, PhD; Xiao-Jun Ma
Summary: Abstract highlights the combination of RNAscope reagents and GeoMx DSP workflow. Demonstrates that the chemistries perform well when the workflow is combined on a single slide and that data concordance between both technologies is robust.
Poster #: P30
Title: Deep Spatial Profiling of the Immune Landscape of MSI and MSS Colorectal Tumors
Authors: Sarah E. Church, PhD; Jason W. Reeves; Daniel R. Zollinger; Jill McKay-Fleisch; Andrew M. White, BSc; Michael D. Bailey; Arya Bahrami, PhD; Chris Merritt, PhD; Margaret Hoang; Sarah Warren, PhD; Joseph M. Beechem, PhD
Summary: Colorectal tumors that were characterized as Microsatellite Stable (MSS) or Microsatellite Instable (MSI) were profiled using IO360 and GeoMx DSP. 60 samples were run on IO360 for bulk gene expression profiling and then profiled using the tumor inflammation signature (TIS) scores, along with MSI status to identify immune hot and cold tumors for further profiling with GeoMx DSP using the new Cancer Transcriptome Atlas assay.
Poster #: P126
Title: Discovery of biomarkers associated with benefit from PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling
Authors: Jon Zugazagoitia, MD, PhD, Yale University School of Medicine, Pathology, Jon Zugazagoitia, MD, Swati Gupta, PhD, Kit Fuhrman, MS PhD, Scott N. Gettinger, MD, Roy S. Herbst, MD, PhD, Kurt A. Schalper, MD, PhD, David L. Rimm, MD, PhD
Summary: Digital Spatial Profiling (DSP) technology identifies spatially-resolved protein markers associated with outcome from single-agent PD-1 checkpoint blockade in NSCLC. High levels of CD56 (top tertile) and CD4 (median) measured in the CD45 compartment were the only markers that were predictive for all clinical outcomes, including longer PFS.
Poster #: P305
Title: Response to Pembrolizumab and tumor microenvironment composition is associated with IL8 expression in a head and neck squamous-cell carcinoma cohort
Authors: Arun Khattri, PhD; Jason W. Reeves; SuFey Ong; Riyue Bao, PhD; Arya Bahrami, PhD; Yi-Hung Carol Tan, PhD; Andrew M. White, BSc; Michael P. Bailey; Heather A. Brauer, PhD; Sarah Warren, PhD; Joseph M. Beechem, PhD; Tanguy Seiwert, MD
Summary: More than 100 head and neck cancer samples were profiled using IO360. There was a modest association between tumor inflammation signature (TIS) and response. There was also a modest association between IL8 expression and progressive disease (PD) status. Follow-up analysis with GeoMx DSP used ISH staining to guide the selection of IL8+ and IL8- ROIs.
At the 2019 SITC Annual Meeting, NanoString will showcase its nCounter platform, IO360 and Data Analysis and GeoMx Digital Spatial Profiler at booth #511.
|
ID |
Abstract Title |
First Author |
Institution |
NanoString |
|
O2 |
Combining transcriptomic and tissue-based immune biomarkers to improve recurrence prediction in stage II-III melanoma |
Robyn Gartrell, MD |
Columbia University |
nCounter |
|
O3 |
Immune infiltration correlates with TP53 mutational status in a multi-cohort acute myeloid leukemia study |
Sergio Rutella, MD, PhD |
Nottingham Trent University |
GeoMx DSP |
|
O74 |
Fibroblast activation protein is expressed by human and murine leukocytes and nonspecific inhibition of FAP enhances anti-PD-1 therapy in murine models of PDAC |
Louis Weiner, MD |
Georgetown |
nCounter |
|
O75 |
Selective induction of S100a8/a9 heterodimer protein in pancreatic cancer in response to immune selection pressure |
Louis Weiner, MD |
Georgetown |
nCounter |
|
O82 |
A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies |
Sarina A. Piha-Paul, MD |
MD Anderson Cancer Center |
nCounter (IO360) |
|
P123 |
Identification of mRNA signatures that predict response to immunotherapy in melanoma patients |
Ioannis A. Vathiotis, MD |
Yale University |
nCounter (IO360) |
|
P125 |
Adenosine and AMP gene expression profiles predict response to adenosine pathway therapies and indicate a need for dual blockade of CD73 and A2AR inhibitors |
Stephen Willingham, PhD |
Corvus Pharmaceuticals |
nCounter |
|
P126 |
Discovery of biomarkers associated with benefit from PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling |
Jon Zugazagoitia, MD, PhD |
Yale University |
GeoMx DSP |
|
P22 |
Transcriptomic Characterization of Immune Response within Diverse Tumor Environments using the NanoString® nCounter® PanCancer IO 360™ Assay |
Jessica Perez, PhD |
NanoString |
nCounter (IO360) |
|
P24 |
Molecularly guided digital spatial profiling for highly multiplexed analysis of gene expression with spatial and single cell resolution |
Anushka Dikshit, PhD |
Advanced Cell Diagnostics |
GeoMx DSP |
|
P260 |
Characterization of AB154, a Humanized, Non-depleting α-TIGIT Antibody Undergoing Clinical Evaluation in Subjects with Advanced Solid Tumors |
Joanne BL. Tan, PhD |
Arcus Biosciences |
nCounter |
|
P289 |
Macrophages modulate patient response to immune checkpoint inhibition in a novel lung tumour explant model |
Lauren Evans, BSc, MSc |
Cardiff University |
nCounter IO360 |
|
P30 |
Deep Spatial Profiling of the Immune Landscape of MSI and MSS Colorectal Tumors |
Sarah Church, PhD |
NanoString |
GeoMx DSP, IO360 |
|
P305 |
Response to Pembrolizumab and tumor microenvironment composition is associated with IL8 expression in a head and neck squamous-cell carcinoma cohort |
Arun Khattri, PhD |
Johns Hopkins Medical Center |
GeoMx DSP, IO360 |
|
P361 |
Molecular and Immunologic Profiling of CD8+ T Cell Responses in Patients Receiving a Multiple Antigen-Engineered Dendritic Cell Vaccine” |
Juraj Adamik, PhD |
Lisa Butterfield, Pitt/PICI |
nCounter |
|
P42 |
An Integrated Multiplexing Approach for the Immunoprofiling of the Tumor Microenvironment of Ovarian Granulosa Cell Tumors |
Juncker-Jensen, PhD |
NeoGenomics |
nCounter (PCIP |
|
P433 |
Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors |
Mark R. Middleton, MD, PhD |
University of Oxford |
nCounter |
|
P454 |
Induction of serum CXCL10 by tebentafusp, a gp100-CD3 bispecific fusion protein, was associated with survival in uveal melanoma in a Phase I/II Study |
Marcus O. Butler, MD |
Princess Margaret Cancer Centre |
nCounter |
|
P481 |
Obesity impairs immunotherapeutic efficacy in pre-clinical breast cancer |
Justin T Gibson, BS |
University of Alabama at Birmingham |
nCounter |
|
P485 |
Synergistic efficacy of anti-PD-L1/IL-15 fusion protein in combination with anti-CTLA-4 antibody in a murine orthotopic 4T1 breast carcinoma model |
Stella Martomo, PhD |
Kadmon Corporation |
nCounter (IO360) |
|
P557 |
A2bR contributes to adenosine-mediated immunosuppression, which is relieved by the dual A2aR/A2bR antagonist AB928 |
Daniel DiRenzo, PhD |
Arcus Biosciences |
nCounter |
|
P583 |
Building a translational pathway using pharmacodynamic and syngeneic tumour models in conjunction with gene expression to enable the development of cancer immune therapies |
Louise Brackenbury, PhD |
Charles River Portishead |
nCounter (M-IO360) |
|
P634 |
Predicting radiation-induced immune trafficking and activation in localized prostate cancer |
Simon P. Keam |
Peter MacCallum Cancer Center |
nCounter (PCIP) |
|
P647 |
Is intracellular STING expression a biomarker for oncolytic herpes virus immunotherapy? |
Praveen Bommareddy, MS, PhD |
Rutgers University |
nCounter |
|
P654 |
CD137 agonists as an adjunct to immune checkpoint inhibitors to overcome resistance in melanoma |
Sreedevi Danturti, PhD |
University of Pennsylvania |
nCounter (IO360) |
|
P666 |
Selective activation of antigen presenting cells by exoSTING enhances tumor antigen-specific immune response |
Su Chul Jang, PhD |
Codiak Biosciences |
nCounter |
|
P706 |
A TCR-CD3 bispecific fusion protein mediates increased presentation of peptide-HLA which associates with improved T cell activation and tumour cell killing |
Duncan M Gascoyne, PhD |
Immunocore |
nCounter |
|
P723 |
Interleukin-6 blockade to de-couple CTLA-4 blockade colitis from anti-tumor efficacy |
Yared Hailemichael, PhD |
MD Anderson Cancer Center |
nCounter (PCIP) |
|
P740 |
Leveraging Artificial Intelligence to Advance Immuno-oncology Drug Development using Functional Ex-Vivo 3D-Tumor Organoid Platforms of Fresh Patient Tissue Samples |
Jenny Kreahling, PhD |
Nilogen Oncosystems |
nCounter |
|
P816 |
DRP-104 Induces Durable Responses In Vivo by Inhibiting Tumor Glutamine Addiction, Remodeling the Tumor Microenvironment and Stimulating Both the Innate & Adaptive Immune Systems |
Yumi Yokoyama, PhD |
Dracen Pharmaceutical |
nCounter |
|
Session 305 Oral |
Session 305: SITC Sparkathon 2018 (SITCure): When is it Safe to Stop Immunotherapy? A Randomized Trial of Early Cessation of Immunotherapy in Patients with Melanoma after 6 Months or More of Stable Disease on Nivolumab Maintenance |
Thomas Marron |
SITC Sparkathon |
nCounter (IO360) |
|
P509 |
Myeloid Cell-Selective STAT3 Inhibition Sensitizes Head and Neck Cancers to Radiation Therapy and Stimulates T-cell-Dependent Tumor Regression |
Marcin Kortylewski, PhD |
Beckman Research Institute |
nCounter |
|
P521 |
MEK inhibition enhances oncolytic herpes virus immunotherapy |
Praveen Bommareddy, MS, PhD |
Rutgers University |
nCounter |
|
P532 |
Increased adiposity reduces the response rate to a combinatorial CTLA-4 based therapy in diet-matched, renal tumor-bearing mice without substantially altering intra-tumoral T cell profiles |
William J. Turbitt Jr., PhD |
University of Alabama at Birmingham |
nCounter |
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science tools for translational research and molecular diagnostic products. The company’s nCounter® Analysis System is used in life sciences research and has been cited in more than 2,800 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s GeoMx™ Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. The company’s technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, GeoMx, nCounter, IO 360 and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contacts
Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768